Caplin Point Q2 Review - Stable Quarter With Strong Margins: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Caplin Point Laboratories Ltd.'s revenues grew 13.2% YoY to Rs 303.5 crore as the company’s unique end to end business model in Latin America continues to drive robust growth.
Ebitda margins improved 72 basis points YoY to 33.3% mainly due to better gross margins. Subsequently, Ebitda grew 15.7% YoY to Rs 101.2 crore.
Net profit grew 31.8% YoY to Rs 75 crore. Delta vis-a-vis Ebitda was on account of higher other income.
Caplin Point posted strong Q2 FY22 results and is now venturing on a capex journey of Rs 300-350 crore to expand existing capacities, widen its product portfolio and backward integrate majority of the products.
Caplin Point is extending its U.S. sterile products into other emerging markets. We continue to remain positive about the company’s unique business model.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.